Chlamydia Infections Pipeline Insight

DelveInsight’s, “Chlamydia – Pipeline Insights, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chlamydia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Chlamydia Understanding

Chlamydia: Overview

Chlamydia is a sexually transmitted infection (STI) caused by a bacteria called chlamydia trachomatis. Usually it doesn't cause any symptoms and can be easily treated with antibiotics. However, if it isn’t treated early it can spread to other parts of your body and lead to long-term health problems.

Symptoms

Signs of chlamydia in women include:

  • increase in vaginal discharge
  • pain or burning when urinating (peeing)
  • pain during sex and/or bleeding after sex
  • pain in the lower stomach – especially when having sex
  • bleeding between periods and/or heavier periods.


Signs of chlamydia in men include:

  • white, cloudy or watery discharge from the penis
  • pain or burning when urinating
  • pain and/or swelling in the testicles.

Diagnosis

Getting tested for chlamydia is easy and doesn’t hurt. A healthcare professional will ask for a urine (pee) sample and/or take a swab from the area that might be infected. This is usually the lower part of the womb (cervix) or the vagina for women, and the tip of the penis (urethra) for men. 

Treatment

Chlamydia can usually be effectively treated with antibiotics. More than 95% of people will be cured if they take their antibiotics correctly.

  • Azithromycin – given as 2 or 4 tablets at once.
  • Doxycycline – given as 2 capsules a day for a week.

Chlamydia Emerging Drugs Chapters

This segment of the Chlamydia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chlamydia Emerging Drugs

  • EVO100: Evofem Biosciences

The investigational drug candidate EVO100 vaginal gel is designed to reduce certain vaginal infections by:

  • Balancing vaginal pH, thereby maintaining healthy vaginal flora and creating an environment that is detrimental to the growth and proliferation of harmful bacteria
  • Using a different mechanism of action that may help to address drug resistance concerns

Further product details are provided in the report……..

Chlamydia: Therapeutic Assessment

This segment of the report provides insights about the different Chlamydia drugs segregated based on following parameters that define the scope of the report, such as:


  • Major Players in Chlamydia

There are approx. 10+ key companies which are developing the therapies for Chlamydia. The companies which have their Chlamydia drug candidates in the most advanced stage, i.e. phase II include, Evofem Biosciences.


  • Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Chlamydia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.


Chlamydia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chlamydia therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chlamydia drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Chlamydia R&D. The therapies under development are focused on novel approaches to treat/improve Chlamydia.

Report Insights

  • Chlamydia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
  • Chlamydia Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Chlamydia drugs?
  • How many Chlamydia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chlamydia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chlamydia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chlamydia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Evofem Inc.
  • Warner Chilcott
  • Shire
  • Okogen
  • NovaBay Pharmaceuticals
  • Melinta Therapeutics
  • Laboratoires Thea
  • IVIEW Therapeutics Inc.
  • Forest Laboratories
  • Endo Pharmaceuticals
  • ActivBiotics Pharma, LLC

Key Products

  • EVO100
  • FST-100
  • OKG-0301
  • NVC-422
  • solithromycin
  • Azithromycin
  • IVIEW-1201
  • Ceftaroline fosamil for Injection|IV Ceftriaxone|Placebo|Clarithromycin
  • PRO 2000
  • Rifalazil

 

Introduction

Executive Summary

Chlamydia: Overview

• Causes

• Mechanism of Action

• Signs and Symptoms

• Diagnosis

• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type

• Assessment by Stage and Product Type

• Assessment by Route of Administration

• Assessment by Stage and Route of Administration

• Assessment by Molecule Type

• Assessment by Stage and Molecule Type

Chlamydia – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• Chlamydia companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Chlamydia Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis

• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Solithromycin - Melinta Therapeutics

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Drug Name: Company Name

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

Drug Name: Company Name

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

• Comparative Analysis

Drug Name: Company Name

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Chlamydia Key Companies

Chlamydia Key Products

Chlamydia- Unmet Needs

Chlamydia- Market Drivers and Barriers

Chlamydia- Future Perspectives and Conclusion

Chlamydia Analyst Views

Chlamydia Key Companies

Appendix

List of Table

 Table 1 Total Products for Chlamydia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List of Figure

Figure 1 Total Products for Chlamydia

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

• Evofem Inc.

• Warner Chilcott

• Shire

• Okogen

• NovaBay Pharmaceuticals

• Melinta Therapeutics

• Laboratoires Thea

• IVIEW Therapeutics Inc.

• Forest Laboratories

• Endo Pharmaceuticals

• ActivBiotics Pharma, LLC

  • Tags:
  • Chlamydia Infections Pipeline
  • Chlamydia Infections clinical trial...
  • Chlamydia Infections companies
  • Chlamydia Infections drugs
  • Chlamydia Infections therapies
  • Chlamydia Infections treatment algo...
  • Chlamydia Infections pipeline drugs

Forward to Friend

Need A Quote